Shares of Celgene Corporation (NASDAQ:CELG) have received a consensus rating of “Buy” from the thirty analysts that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and twenty-two have issued a buy recommendation on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $140.95.
CELG has been the topic of several analyst reports. Cann reissued a “buy” rating and issued a $148.00 target price on shares of Celgene Corporation in a research report on Tuesday, April 4th. Oppenheimer Holdings, Inc. restated an “outperform” rating and set a $148.00 price target on shares of Celgene Corporation in a report on Wednesday, April 5th. Jefferies Group LLC restated a “buy” rating and set a $154.00 price target on shares of Celgene Corporation in a report on Tuesday, April 11th. Robert W. Baird restated an “outperform” rating and set a $162.00 price target on shares of Celgene Corporation in a report on Wednesday, April 19th. Finally, Barclays PLC restated an “equal weight” rating and set a $125.00 price target (up from $120.00) on shares of Celgene Corporation in a report on Sunday, April 23rd.
In related news, Director James J. Loughlin sold 18,500 shares of the company’s stock in a transaction dated Monday, June 26th. The shares were sold at an average price of $133.57, for a total transaction of $2,471,045.00. Following the transaction, the director now owns 32,877 shares in the company, valued at approximately $4,391,380.89. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Rupert Vessey sold 4,785 shares of the company’s stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $120.18, for a total transaction of $575,061.30. Following the transaction, the insider now owns 4,004 shares in the company, valued at approximately $481,200.72. The disclosure for this sale can be found here. In the last ninety days, insiders sold 237,005 shares of company stock worth $31,515,142. 0.95% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. Edge Wealth Management LLC increased its position in shares of Celgene Corporation by 10.5% in the first quarter. Edge Wealth Management LLC now owns 15,920 shares of the biopharmaceutical company’s stock valued at $1,979,000 after buying an additional 1,518 shares during the period. Swiss National Bank increased its position in shares of Celgene Corporation by 27.2% in the first quarter. Swiss National Bank now owns 2,746,896 shares of the biopharmaceutical company’s stock valued at $341,796,000 after buying an additional 588,000 shares during the period. Catawba Capital Management VA increased its position in shares of Celgene Corporation by 12.0% in the first quarter. Catawba Capital Management VA now owns 2,425 shares of the biopharmaceutical company’s stock valued at $302,000 after buying an additional 260 shares during the period. Train Babcock Advisors LLC bought a new position in shares of Celgene Corporation during the first quarter valued at about $205,000. Finally, Personal Capital Advisors Corp increased its position in shares of Celgene Corporation by 11.3% in the first quarter. Personal Capital Advisors Corp now owns 233,811 shares of the biopharmaceutical company’s stock valued at $29,014,000 after buying an additional 23,686 shares during the period. Institutional investors and hedge funds own 78.16% of the company’s stock.
Celgene Corporation (CELG) traded up 1.05% during trading on Friday, reaching $137.74. 3,641,330 shares of the company’s stock were exchanged. Celgene Corporation has a 52 week low of $96.93 and a 52 week high of $138.17. The company’s 50 day moving average price is $127.82 and its 200-day moving average price is $122.28. The stock has a market capitalization of $107.55 billion, a price-to-earnings ratio of 51.72 and a beta of 1.89.
Celgene Corporation (NASDAQ:CELG) last released its earnings results on Thursday, April 27th. The biopharmaceutical company reported $1.68 earnings per share for the quarter, topping the consensus estimate of $1.47 by $0.21. The business had revenue of $2.96 billion for the quarter, compared to the consensus estimate of $3.04 billion. Celgene Corporation had a net margin of 18.32% and a return on equity of 70.94%. The firm’s quarterly revenue was up 17.8% compared to the same quarter last year. During the same period last year, the firm posted $1.32 earnings per share. On average, equities analysts expect that Celgene Corporation will post $7.28 EPS for the current year.
About Celgene Corporation
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
